Herein we report a case of a patient with hepatic metastasis of colonic carcinoma and LS due to MSH2 and EPCAM genes mutation who is enjoying an ongoing, prolonged treatment response of almost two years to single-agent pembrolizumab, even though he underwent treatment related adverse event (TRAE) during the treatment period of monotherapy. This evidence concerns the gene MSH2 and Leigh syndrome.